Skip to content

Space meets Glaucoma

Space meets Glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00028040
Enrollment
16
Registered
2022-02-24
Start date
2021-06-04
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H40.1

Interventions

Group 1: After enrolment in the study, participants will stay in the DLR research bed rest facility for 3 days and 2 nights. There will be a 50:50 randomization in two groups as a cross over design.

Sponsors

DLR, Institut für Luft- und Raumfahrtmedizin(German Aerospace Center, Institute of Aerospace Medicine) Klinische Luft- und Raumfahrtmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with ocular hypertension, primary open-angle glaucoma or secondary openangle glaucoma with pigment dispersion glaucoma and pseudoexfoliation glaucoma with or without topical antiglaucoma drugs. - Verified nocturnal peeks in intraocular pressure in lying position in comparison with values of intraocular pressure at day in at least one eye (5 mmHg on average). - Consent to participating in this study. - Ability to understand the patient information and study procedures and to give consent or consent given by an independent guardian of the patient to participate in this study.

Exclusion criteria

Exclusion criteria: - Inability to lay in bed for 6 hours without getting up. - Spinal cord diseases - Other forms of glaucoma than the ones specified above - Previous Glaucoma surgeries (exceptions: cataract surgery, surgery of the trabecular meshwork, SLT) - Missing willingness and consent to participate in the study - Allergy against eye drops especially local anaesthetic eye drops - Diabetes mellitus - No other medical conditions that need treatment during the study period besides medical treatment

Design outcomes

Primary

MeasureTime frame
Primary Endpoint: A decrease of intraocular pressure (IOP) of > 3 mm Hg in nocturnal upper body and head up tilt of +10° compared to normal sleeping position.

Secondary

MeasureTime frame
A decrease in blood pressure of > 10% of the daily mean systemic blood pressure and a change in choroidal blood patter.

Countries

Germany

Contacts

Public ContactClaudia Stern

DLR, Institut für Luft- und RaumfahrtmedizinKlinische Luft- und Raumfahrtmedizin

Claudia.Stern@dlr.de+49 2203 601 3368

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026